Get started
Author

Charlotte N. Stahlfeld

Observed names: C. Stahlfeld, Charlotte N Stahlfeld, Charlotte Stahlfeld, Stahlfeld, Charlotte N.
ORCID: 0000-0002-6433-3117
Observed ORCID: 0000-0002-6433-3117
OpenAlex ID: A5089107759
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
2021 · Jamie M. Sperger, Hamid Emamekhoo, et al. · Journal of Clinical Oncology · 61
PDF
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
2023 · Talal El Zarif, Amin H Nassar, et al. · JNCI Journal of the National Cancer Institute · 59
PDF
Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
2022 · Tamara S. Rodems, Erika Heninger, et al. · Communications Biology · 56
PDF
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
2023 · Jamie M. Sperger, Kyle T. Helzer, et al. · Clinical Cancer Research · 53
PDF
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer
2022 · Shuang G. Zhao, Jamie M. Sperger, et al. · Journal of Clinical Investigation · 36
PDF
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
2021 · Rory M. Bade, Jennifer L. Schehr, et al. · Molecular Oncology · 24
Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction
2018 · Hannah M. Pezzi, David J. Guckenberger, et al. · Lab on a Chip · 22
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer
2021 · Mark Daniel, Todd P Knutson, et al. · Endocrine Related Cancer · 13
Pairing Microwell Arrays with an Affordable, Semiautomated Single-Cell Aspirator for the Interrogation of Circulating Tumor Cell Heterogeneity
2020 · Jacob J. Tokar, Charlotte N. Stahlfeld, et al. · SLAS TECHNOLOGY · 12
1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
2024 · J.M. Lang, S.T. Tagawa, et al. · Annals of Oncology · 8
PDF
SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples
2022 · Tamara S. Rodems, Duane S. Juang, et al. · Clinical Epigenetics · 6
PDF
Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.
2017 · Waddah Arafat, Charlotte Stahlfeld, et al. · Journal of Clinical Oncology · 5
Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancer
2023 · Jamie M. Sperger, Amy K. Taylor, et al. · Cancer Research · 4
TROP-2 co-expression with androgen receptor splice variants as a new therapeutic target in prostate cancer.
2021 · Charlotte Stahlfeld, Jamie Sperger, et al. · Journal of Clinical Oncology · 2
Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).
2023 · Charlotte Stahlfeld, Hamid Emamekhoo, et al. · Journal of Clinical Oncology · 1
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
2023 · Amy K Taylor, Jamie M Sperger, et al. · Journal of Clinical Oncology · 1
PDF
Bridging the Loneliness Gap: Depression, Connectivity, and Isolation in Pediatric Oncology Patients and Their Peers
2026 · Charlotte N. Stahlfeld, Scott H. Maurer, et al. · Pediatric Blood & Cancer
Longitudinal Phenotyping of Circulating Tumor Cells Using a Scalable Deep Learning Framework
2026 · Matthew L. Bootsma, Marina N. Sharifi, et al. · Clinical Cancer Research
Private Equity Acquisition Effect on the Most Common Urologic Procedures
2026 · Shyam Patnaik, Danielle R. Sharbaugh, et al. · Urology
Figure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
2025 · Jamie M. Sperger, Kyle T. Helzer, et al.
PDF
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
2025 · Jamie M. Sperger, Kyle T. Helzer, et al.
PDF
Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
2025 · Jamie M. Sperger, Kyle T. Helzer, et al.
PDF
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
2025 · Jamie M. Sperger, Kyle T. Helzer, et al.
PDF
Data from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
2024 · Jamie M. Sperger, Kyle T. Helzer, et al.
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
2024 · Jamie M. Sperger, Kyle T. Helzer, et al.
Works count: 60
Citation count: 363
H-index: 9
I10-index: 9
Year
Topic
Type